Description: Why Kenvue Is On Investors’ Radar Today Kenvue (KVUE) has drawn fresh attention after recent share price moves that left its past 3 months return ahead of its performance over the past year, prompting investors to recheck the consumer health story. See our latest analysis for Kenvue. The recent 21.33% 3 month share price return contrasts with a weaker year to date share price return of 1.15% decline and a 1 year total shareholder return of 14.49% decline, suggesting improving short term...

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently looked at. During the episode, a caller asked if they should hold or sell it. In response, Cramer said: “Okay, so I think a lot of the weakness is more involved with Kenvue, but remember, Procter, which we own for the Charitable Trust, also […]

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is included among the 13 Best Consumer Staples Dividend Stocks to Invest in Now. On January 5, Wells Fargo cut its price target on Kimberly-Clark Corporation (NASDAQ:KMB) to $105 from $110 and kept an Equal Weight rating on the shares. The change reflects updates to Wells’ models across Beverage, Food, and Home […]

Description: Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]

Description: If you are wondering whether Kenvue's current share price reflects fair value or a potential opportunity, you are in the right place. The stock closed at US$16.74 with returns of a 3.0% decline over 7 days, a 0.1% decline over 30 days, a 3.3% decline year to date and a 17.4% decline over the last year, which may have shifted how investors think about its risk and return trade off. Recent coverage around Kenvue has focused on its position as a stand alone consumer health company following its...

Description: Kenvue has appointed Madhav Nayak as Vice President and Chief Marketing Officer for the Asia-Pacific region, bringing experience from Yum! Brands, Meta and a more than 12-year tenure at Unilever into its regional leadership team. This hire could meaningfully influence how Kenvue executes its marketing, digital and commercial agenda across Asia-Pacific, a core growth-focused geography for the consumer health group. We will now explore how Madhav Nayak’s appointment as Asia-Pacific CMO might...

Description: The maker of bathroom products is about to undergo a significant change in its business.

Description: These five top Dividend Kings with yields up to 7% looked poised to deliver strong total return and passive income in 2026.

Description: A report that Toms Capital has taken a stake comes as the retailer faces sluggish sales and market-share losses.

Description: Target faces heightened scrutiny as activist investor Toms Capital builds a stake. Does this mark a turning point, or justify continued caution?

Description: US retail chain Target is facing pressure from an activist investor after a sales slump that has wiped out nearly a third of its share value...

Description: Investing.com -- Target shares are gaining roughly 3.3% in early trading on Friday after the Financial Times reported that activist investor Toms Capital Investment Management has acquired a significant stake in the retail chain.

Description: Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the market is more focused on the tailwind of policy easing than the headwind of weakening fundamentals, resulting in substantial gains despite stagflation emerging as a key concern. […]

Description: Kenvue (KVUE) has been drifting after a tough year in the market, and that slump is exactly why the stock is getting a closer look from value-focused investors right now. See our latest analysis for Kenvue. At around $17.02, Kenvue’s share price reflects a modest 1 month share price return against a much weaker year to date share price return. This suggests sentiment is stabilising rather than improving meaningfully even as the business keeps posting steady revenue and earnings growth. If...

Description: If you are wondering whether Kenvue at around $17 is a bargain in disguise or a value trap, you are not alone. That is exactly what we are going to unpack here. Over the last week the stock dipped about 1.3%, but it is still up roughly 2.3% over the past month, even though it remains down about 20% year to date and 17.8% over the last year. Recent headlines have focused on Kenvue as a newly independent consumer health company reshaping its portfolio and cost base. At the same time, investors...

Description: Company vows appeal after jury decision

Description: A Baltimore jury found Johnson & Johnson liable for failing to warn about asbestos risks tied to talc-based baby powder.

Description: Company plans to appeal Maryland jury ruling tied to asbestos exposure claims.

Description: With shares near record highs and a buyout clock quietly ticking, this position says more about risk control and deal math than chasing momentum.

Description: Packaged-food producers outperform during rotations to safety. But shifts in consumer habits mean investors need to be selective.

Description: Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.

Description: Kimberly-Clark's latest valuation update reflects only a slight trim to its fair value estimate, nudging it from about $128.87 to $127.73 per share, even as assumptions for long term revenue growth climb from roughly 7.0% to around 10.4%. With the discount rate effectively steady near 6.956%, the shift in price target appears driven more by caution over Kenvue related execution risk than by any loss of confidence in the company’s growth outlook. Read on to see how you can track these evolving...

Description: After recently coming under pressure, these three dividend stocks have both yield and rebound potential.

Description: Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm […]

Description: Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like these now.

Description: Kenvue (KVUE) keeps drifting lower even after reporting steady revenue and profit growth, which raises a simple question for investors: is the market underpricing a slow but dependable consumer health story? See our latest analysis for Kenvue. Despite the latest print showing modest revenue and earnings growth, Kenvue’s 1 year total shareholder return of minus 22.8 percent and weaker year to date share price return suggest sentiment is still fading rather than turning. If this kind of steady...

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is included among the 15 Blue Chip Dividend Stocks to Build a Passive Income Porfolio. On December 1, Kimberly-Clark Corporation (NASDAQ:KMB)’s price target was reduced by BNP Paribas Exane to $110 from $127. The firm reaffirmed a Neutral rating on the stock. The adjustment followed the company’s planned acquisition of Kenvue, which […]

Description: As Kenvue has performed weaker than the consumer defensive sector over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Description: We came across a bullish thesis on Kenvue Inc. on The Value Road’s Substack. In this article, we will summarize the bulls’ thesis on KVUE which was published before KVUE’s acquisition announcement. Kenvue Inc.’s share was trading at $17.35 as of November 28th. KVUE’s trailing and forward P/E were 23.13 and 15.77 respectively according to Yahoo Finance. Kenvue Inc. […]

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is included among the 15 Best Boring Dividend Stocks to Buy. On⁠ November 13, Argus analy⁠st John St‌aszak upgraded Kimberly-Clark Corporation (NASDAQ:KMB) to a Buy ratin‍g​ from Hold and set a $120 price targ‌et, according to a report by The Fly. He pointed out that the stock has b‌een l‍agging lately, but […]

Description: Kenvue stock has recently seen its fair value estimate trimmed from $19.42 to $19.33 per share as market analysts adjust to evolving legal and growth considerations. This subtle reduction reflects increased caution amid ongoing litigation and shifts in sales expectations. The discount rate has also edged up to 8.06 percent, signaling a slightly higher perceived risk for investors. Stay tuned to learn how you can track these updates and navigate changes in the Kenvue investment narrative going...

Description: Ever wondered if Kenvue is a hidden value play or if its recent price is telling us something different? Today, we are unpacking whether the current share price is a bargain or a warning sign for investors. Kenvue’s stock price has caught some attention lately, climbing 4.9% over the last week and jumping 13.5% for the past month. This comes despite a drop of 20.0% year-to-date and 26.5% over the last year. In recent weeks, headlines have highlighted Kenvue’s continued integration efforts...

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said: “Alright, this is one we’ve talked about a bunch, Kimberly-Clark’s bold, nearly $49 billion bid to buy Kenvue, which is the J&J’s old over-the-counter business that makes Tylenol, […]

Description: Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if long-term shareholders should be worried. Here’s what Mad Money’s host had to say in response: “Okay, it’s a really important question because I’ve been looking to buy Kimberly. I think the answer is no. […]

Description: Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]

Description: In a recent legal decision, a Texas judge ruled that Kenvue can proceed with a planned US$400 million shareholder dividend despite ongoing litigation regarding Tylenol's alleged link to autism, with the dividend scheduled for November 26, 2025. This move offers reassurance to investors about Kenvue's financial stability and flexibility to return capital even while facing unresolved legal risks. We'll explore how the court's approval of this significant dividend payment during active...

Description: We recently published 16 Latest Stocks on Jim Cramer’s Radar. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks on Jim Cramer’s radar. After Kimberly-Clark Corporation (NASDAQ:KMB) announced its mega $48.7 billion acquisition of Kenvue, Jim Cramer hasn’t been able to help himself when discussing the firm. While the shares appeared to react negatively to the […]

Description: We recently published 11 Stocks Jim Cramer Talked About. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently discussed. After personal care products firm Kimberly-Clark Corporation (NASDAQ:KMB) announced its $48.7 billion acquisition of Kenvue last week, Cramer couldn’t stop praising the decision as he commented that the deal enabled the two firms to […]

Description: We recently published 11 Stocks Jim Cramer Talked About. The Procter & Gamble Company (NYSE:PG) is one of the stocks Jim Cramer recently discussed. The Procter & Gamble Company (NYSE:PG) is one of the biggest consumer goods companies in the world. Cramer has praised the firm’s management in previous appearances. More recently, he discussed The […]

Description: A Texas judge will weigh Texas Attorney General Ken Paxton's bid to block Kenvue's (KVUE) November d

Description: Starboard’s Jeff Smith says activism isn’t about destruction — it’s about discipline, efficiency, and motivating complacent CEOs.

Description: Starboard Value managing member, CEO, and chief investment officer Jeffrey Smith is among the most influential activist investors on Wall Street. Smith sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss what drew him to activist investing, how he selects investment targets, the Kenvue (KVUE) and Kimberly-Clark (KMB) deal, and more. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently put under a microscope. Cramer discussed the company’s planned acquisition, as he commented: “Sometimes when stocks are doing badly, I get worried, not because I want to get out, but because I wonder if I might be missing a once-in-a-generational bottom. Those don’t come […]

Description: We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Haleon plc (NYSE:HLN) is a consumer products company that sells items such as toothpaste and pain relief products. The firm owns several well-known brands such as Sensodyne […]

Description: Kenvue (KVUE) shares have been on a bit of a rollercoaster lately, with the stock losing almost 21% over the past 3 months. Investors are left weighing the household products maker’s current valuation in relation to its recent earnings growth. See our latest analysis for Kenvue. Kenvue’s share price has been struggling to regain momentum, with a 1-year total shareholder return down nearly 25% and the 20% slide over the past three months highlighting fading optimism. While brief rebounds have...

Description: Dividend stocks might not sound like an exciting investment in your portfolio, but if you can invest in the right ones, they can generate years of passive income. The Nasdaq Composite index includes the stocks listed on the Nasdaq stock exchange and has some of the biggest and the best U.S. companies. The government uncertainty ... 4 Highest Yielding Dividend Stocks in the Nasdaq Composite

Description: We recently published 10 Stocks Soaring Past Expectations. Kenvue Inc. (NYSE:KVUE) is one of the big names that led last week’s charge. Kenvue grew its share prices by 17.47 percent week-on-week, as investors loaded portfolios following twin news that it achieved a strong earnings performance in the past quarter of the year, alongside plans to […]

Description: Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the stock’s struggles, as he commented: “With Kimberly-Clark shelling out nearly $49 billion to buy Kenvue, which was originally J&J’s over-the-counter medicine business, I think it’s time to check in with Haleon, the former consumer business of GlaxoSmithKline and Pfizer… Oh, […]

Description: Kenvue Inc. (NYSE:KVUE) is one of the Best Low Priced Stocks to Buy According to Analysts. On November 3, the company announced financial results for Q3 2025, with gross profit margin expanding 60 bps to 59.1% from 58.5% in the previous-year period. Notably, adjusted gross profit margin expanded 50 bps to 61.2% from 60.7% in the […]

Description: Kenvue stock has recently experienced a shift in analyst sentiment, leading to a reduction in the consensus price target from $20.63 to $19.42 per share, a decrease of approximately 5.9%. This adjustment reflects both the evolving legal landscape and a mix of optimism and caution among market watchers regarding the company's future growth potential. Stay tuned to discover how you can remain informed as the narrative around Kenvue continues to evolve. Analyst Price Targets don't always capture...

Description: Data from the National Association of Realtors reveal a struggling housing market. Sales are down, prices up, and down payments are rising. That means younger buyers have to wait.

Description: Trade-sensitive stocks rose Wednesday as the Supreme Court heard oral arguments on the case challenging the broad array of global tariffs President Trump has imposed. The levies appeared to be on shaky ground after the hearing, during which justices expressed skepticism about Trump’s authority to impose sweeping measures on countries around the world. The Trump administration’s top lawyer faced sharp questioning, including from some members of the court’s conservative wing.

Description: We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently discussed. Kimberly-Clark Corporation (NASDAQ:KMB)’s $48.7 billion Kenvue acquisition announcement was well-received by Jim Cramer despite the stock’s negative reaction. The CNBC TV host believes that the deal allows the firm to […]

Description: For a sector known for safety, consumer staples have been living dangerously. It’s been a tough year for consumer staples. The exchange-traded fund is down 1.7% this year, while all other sectors were in the green as of Wednesday’s close.

Description: Wondering whether Kenvue stock is a hidden gem or an overhyped pick? You are not alone, especially with so much chatter about finding value in today’s market. Kenvue’s share price has seen some wild swings recently, including a sharp 13.4% jump in the last week, a smaller 3.4% gain over the past month, and yet it is still down 23.7% year-to-date and 25.2% over the past year. Most of these dramatic moves came after headlines about Kenvue’s brand strategy shift and the resolution of certain...

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the latest stocks on Jim Cramer’s radar. Cramer discussed the company’s earnings, acquisition plans, and market reaction after both. He commented: “How about Kimberly-Clark? Sure, it got hit hard off the announcement of the Kenvue acquisition yesterday, but consider this. This, Kimberly just reported that it earned a $1.82 […]

Description: Attorney General Ken Paxton filed a motion in a Texas District court on Wednesday to prevent Kenvue

Description: Trump’s 2025 comments sent shockwaves through the market—see which major stocks, from Disney to Tesla, were impacted.

Description: Ultra-high yields don't have to translate to ultra-high risk.

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently commented on. Cramer highlighted the company’s acquisition plans, as he commented: “Now, I want you to contrast that with Kimberly-Clark, a great company, saw its stock get clobbered today after the company announced it was buying Kenvue. That’s the maker of Tylenol, Band-Aids, Neutrogena, […]

Description: Both Kimberly Clark and Kenvue are Dividend Aristocrats. Dividends after a merger could well disappoint.

Description: We recently published 11 Latest Stocks Jim Cramer Talked About. Kenvue Inc. (NYSE:KVUE) is one of the stocks Jim Cramer recently discussed. Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently. The firm faced turmoil on the stock market in September after President Trump raised concerns […]

Description: We recently published 11 Latest Stocks Jim Cramer Talked About. The Procter & Gamble Company (NYSE:PG) is one of the stocks Jim Cramer recently discussed. The Procter & Gamble Company (NYSE:PG) is one of the largest consumer goods companies in the world. In his previous comments, Cramer has called the firm one of “the best” […]

Description: We recently published 11 Latest Stocks Jim Cramer Talked About. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently discussed. Along with OpenAI’s Amazon deal, Kimberly-Clark Corporation (NASDAQ:KMB) also made headlines after it announced that it would acquire household and personal products company Kenvue for $48.7 billion. Cramer discussed Kimberly-Clark Corporation (NASDAQ:KMB)’s CEO […]

Description: Kimberly-Clark’s stock is down 1.7% to $100.55 after hitting a new 52-week low earlier in the session on Tuesday. Investors wondered why Kimberly-Clark was willing to buy a company with weakening sales and sizable potential legal liability related to Tylenol and talc. The deal requires shareholder approval from both Kimberly-Clark and Kenvue.

Description: Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.

Description: A price-sensitive, value-conscious consumer adds a degree of unevenness and uncertainty to a robust earnings season.

Description: In other news, Apple suppliers Qorvo and Skyworks plan to combine and metal card maker Composecure offers a bid for Husky Technologies.

Description: For the 12th consecutive quarter, Berkshire Hathaway was a net seller of stocks, offloading $6 billion worth.

Description: The deal, expected to close in the second half of 2026, comes as Kenvue's Tylenol political fight is heating up.

Description: We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Kenvue Inc. (NYSE:KVUE) is one of the best-performing on Monday. Kenvue saw its share prices jump by 12.32 percent on Monday to close at $16.14 apiece as investors loaded portfolios following news that it was set to […]

Description: Combined company aims to become global health leader by 2026.

Description: The Morning Bull - US Market Morning Update Tuesday, Nov, 4 2025 US stock futures are sliding premarket as investors digest hawkish signals from the Federal Reserve and ongoing signs of strain in the manufacturing sector. With Fed officials making it clear that a December rate cut is not guaranteed, and manufacturing data painting a mixed, uncertain picture, market sentiment is becoming more cautious as investors weigh the impact of elevated yields and weaker production on broader economic...

Description: The latest investor updates on stocks that are trending on Tuesday

Description: Kimberly-Clark is creating a consumer health and wellness giant.

Description: One scoop to start: An influential group representing some of the private equity industry’s largest backers has sounded the alarm about the risks...

Description: Kimberly-Clark, manufacturer of consumer goods and personal care products, is best known for its paper-based products, including Scott, Cottonelle, Kleenex, Kotex, Huggies, and Pull-ups. The company is now expanding its portfolio with more everyday American products through a strategic ...

Description: Mike Hsu aims to stoke the consumer company’s growth by veering into Kenvue’s higher-margin but risky health products.

Description: Kenvue (KVUE) reported a net profit margin of 9.4%, up from 7.3% last year. One-year earnings growth reached 26.3%, and the company has a forecasted annual profit growth rate of 11.3%. The share price is $16.14, well below analyst fair value estimates of $26.80. Despite a one-off loss of $595.0 million in the past year, investors might find encouragement in improved profitability, accelerating profit growth, and the current valuation discount compared to analyst targets. See our full analysis...

Description: Huggies maker Kimberly-Clark announced Monday it will buy Tylenol’s parent company Kenvue in a nearly $50 billion deal, creating a massive consumer products conglomerate.

Description: One of biggest takeovers so far this year will create a global company with annual revenues of roughly $32 billion.

Description: The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com

Description: Kimberly-Clark shares suffered their biggest one-day drop since the 1980s after the Huggies diapers maker agreed to buy Kenvue. Shares in the Tylenol maker leapt. At the close of trading: Kimberly-Clark's stock fell 15% to $102.

Description: The S&P 500 Index ($SPX ) (SPY ) on Monday rose +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) fell -0.52%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.37%. December E-mini S&P futures (ESZ25 ) rose +0.09%, and December E-mini Nasdaq futures (NQZ25 ) rose...

Description: ↗️ Kenvue (KVUE): Shares of the Tylenol maker jumped 12% on the news that Kimberly-Clark (KMB) would purchase the company. Shares in the Huggies maker skidded, falling nearly 15%. ↗️ Amazon.com (AMZN): OpenAI agreed to pay $38 billion for computing power in a multiyear deal that marks the first partnership between the startup and the cloud giant.

Description: US equity indexes traded mixed at Monday's close as Amazon.com's (AMZN) $38 billion deal with the Mi

Description: Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

Description: An AI collaboration boosted the company behind the largest U.S. cloud service on Monday, Nov. 3, 2025, while shares of the two companies involved in a consumer goods deal saw major moves.

Description: Nvidia and other AI superstar stocks propped up Wall Street. The S&P 500 rose 0.2% Monday, even though the majority of stocks within the index fell. The Dow Jones Industrial Average dropped 0.5%, and the Nasdaq composite rose 0.5%.

Description: US equity indexes closed mixed on Monday, bolstered by a surge in Amazon.com's (AMZN) shares followi

Description: US stocks made gains, with Wall Street looking to maintain upward momentum.

Description: Consumer stocks were mixed late Monday afternoon, with the Consumer Staples Select Sector SPDR Fund

Description: Kimberly-Clark is buying Tylenol maker Kenvue for nearly $50 billion. The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt. Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.

Description: Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Description: The purchase of Kenvue by Kimberly-Clark announced Monday would mark the close of a short, rocky term of independence for the Tylenol maker, which was spun off from Johnson & Johnson in 2023. Kenvue shares have been under pressure since President Trump’s warning that acetaminophen—the active ingredient in Tylenol—is a potential cause of autism. Kenvue has called the claims baseless.

Description: Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares heading into 2026.

Description: Despite Kenvue’s underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Description: Kenvue Inc. (NYSE:KVUE) is one of the 10 Stocks Under $20 to Buy According to Analysts. On October 27, Jefferies reduced its price target on Kenvue Inc. (NYSE:KVUE) from $25 to $23 and kept a Buy rating. Jefferies noted that retail trends are showing signs of weakness. The research firm highlighted a 1.5% drop, which […]

Description: Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Kenvue Inc. (NYSE:KVUE) is one of the best up and coming stocks to buy right now. On October 27, Jefferies analyst Keith Devas lowered the firm’s price target on Kenvue to $23 from $25 and maintained a Buy rating on the shares, as the current macroeconomic challenges are impacting consumer health stocks more than the […]

Description: Kenvue Inc. (NYSE:KVUE) is one of the most buzzing stocks to buy with huge upside potential. On October 24, Deutsche Bank lowered the firm’s price target on Kenvue to $18 from $20 and kept a Hold rating on the shares. Earlier on October 10, JPMorgan also lowered the firm’s price target on Kenvue to $21 […]

Description: Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls

Description: Across pharmacies, supermarkets and online marketplaces, Tylenol continues to sell steadily despite political commentary, litigation and a rolling safety debate.

Description: When the S&P 500 is rallying to all-time highs, you have to wonder about the stocks getting left out. Turns out analysts see great promise.

Description: SUMMIT, N.J., October 29, 2025--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025.

Description: Kenvue (NYSE:KVUE) is in the spotlight following a new lawsuit from the Texas Attorney General that alleges Tylenol, one of its key brands, may be linked to autism. Ongoing legal questions, recent management changes, and updated medical guidance on Tylenol have created a cloud of uncertainty around the company’s stock this month. See our latest analysis for Kenvue. It’s been a turbulent stretch for Kenvue, with the share price dropping nearly 33% over the past 90 days and total shareholder...

Description: Roughly 1,300 cases of the recalled product were distributed across four states.There is a health risk: The bacterium Pluralibacter gergoviae can cause infections in vulnerable people. However, the Food and Drug Administration classifies the recall as Class II (low risk).Beauty-product recalls ...

Description: The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.

Description: The suit alleges that Kenvue hid autism risks of its popular pain reliever despite doctors saying it is safe to take during pregnancy.

Description: Texas joined the Trump administration in claiming Tylenol causes autism. Shares of Kenvue fell 3.2% Tuesday to $14.60 after Texas Attorney General Ken Paxton filed a suit alleging that the maker of Tylenol engaged in deceptive advertising that said the over-the-counter drug was safe to use while pregnant. The suit also named Johnson & Johnson which spun off Kenvue in 2023.

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the state of Texas suing Johnson & Johnson (JNJ) and Kenvue (KVUE) over allegations that the companies hid the connections between Tylenol and Autism for pregnant women, D.R. Horton (DHI) topping quarterly home orders estimates, and Trump Media & Technology Group (DJT, DJTWW) offering predictions market features on Truth Social. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: (Update with Kenvue's and Johnson & Johnson's responses to requests for comment from MT Newswires in

Description: Quality and value underperformed in the third quarter. But there’s more to the market than Nvidia and AI.

Description: SUMMIT, N.J., October 27, 2025--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.

Description: If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.

Description: Dividend investing offers a reliable path to passive income and long-term wealth building, especially when stock prices stagnate or decline. Regular payouts provide cash flow regardless of market direction, and reinvesting dividends historically drives much of total return. High-yield stocks, however, carry risks. Yields above 5% often signal underlying issues—declining earnings, high debt, or sector-specific ... 3 Dividend Stocks With Yields Over 5%. Should You Buy?

Description: Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story).

Description: Kenvue Inc. (NYSE:KVUE) is one of the best affordable stocks to buy under $20. Canaccord Genuity analyst Susan Anderson reiterated a Buy rating on Kenvue Inc. (NYSE:KVUE) on October 17, setting a $26 price target. Anderson supported the rating with the company’s market position and current legal challenges, stating that she believes that the judge-led […]

Description: Kenvue stock has recently seen its consensus analyst price target decrease modestly from $21.70 to $20.63. This slight adjustment reflects a mix of new insights, as analysts weigh fresh legal and reputational risks against potential value opportunities from strategic changes. Stay tuned to discover how investors and observers can best monitor the evolving narrative around Kenvue in the coming months. What Wall Street Has Been Saying The past several weeks have brought a flurry of updates from...

Description: Albert Invent announced in early 2025 a multi-year partnership with Kenvue Inc. to integrate advanced AI models into Kenvue’s global R&D processes, aiming to streamline and accelerate product development across its brand portfolio. This collaboration comes as Kenvue faces legal, regulatory, and operational headwinds, highlighting the company’s push for innovation amid ongoing uncertainty about the future of its core brands. We'll examine how heightened legal and regulatory risk related to...

Description: Kenvue is expected to announce its third-quarter results by early November, and analysts expect a notable decline in earnings.

Description: The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Description: Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy.

Description: We came across a bullish thesis on Kenvue Inc. on X.com by ZeeContrarian1. In this article, we will summarize the bulls’ thesis on KVUE. Kenvue Inc.’s share was trading at $16.23 as of September 30th. KVUE’s trailing and forward P/E were 21.89 and 14.81 respectively according to Yahoo Finance. Donald Trump, despite having no medical background, has […]

Description: If you’re eyeing Kenvue stock and asking yourself what to do next, you’re definitely not alone. There has been more than a little turbulence lately, and for anyone considering an entry or exit, understanding what’s really driving the recent moves is essential. Over just the past week, Kenvue’s price slipped another 7.6%, capping off a challenging month down 18.6%. The story only grows more dramatic when you zoom out to the full year, with shares off by nearly one-third since January. So,...

Description: Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the Health Car

Description: Kenvue urged the Food and Drug Administration to deny a proposal to add further warnings to acetaminophen products after the Trump Administration linked Tylenol use during pregnancy to autism.

Description: Kenvue Faces a Defining Moment: Leadership Shakeup and Strategic Review Signal Pressure for Change

Description: These three stocks have elevated yields and attractive dividend histories.

Description: The Morning Bull - US Market Morning Update Monday, Oct, 20 2025 US stock futures are in positive territory before the opening bell as investors react to a fresh wave of economic signals that reinforce expectations for Federal Reserve rate cuts. Hopes for easier monetary policy have been fueled by sliding Treasury yields and subdued manufacturing activity. However, persistent uncertainty around the banking sector and delayed government data is keeping market sentiment cautious while investors...

Description: Kenvue could start to recover in 2026.

Description: Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded after a flurry of corporate earnings reports.

Description: Kenvue Inc. (NYSE:KVUE) is one of the best high volume stocks to buy according to Wall Street analysts. On October 10, JPMorgan lowered the price target on Kenvue to $21 from $24, while maintaining an Overweight rating on the shares as part of a Q3 2025 preview for the household, personal care, and beauty group. […]

Description: The Morning Bull - US Market Morning Update Friday, Oct, 17 2025 US stock futures are under pressure heading into Friday’s open, with persistent fears around credit market stress taking center stage. Investors are grappling with falling Treasury yields and a wave of fresh economic warning signs. A sharp drop in regional manufacturing data and rising expectations for rate cuts are fueling uncertainty and putting a chill on risk appetite as they weigh the outlook for growth and financial...